Nicotinamide-based VEGFR-2 inhibitors have good contribution in drug discovery. Development of novel nicotinamides as VEGFR-2 inhibitors. different and assays were conducted to evaluate the VEGFR-2 inhibition and cytotoxicity. Compound displayed strongest anti-VEGFR-2 potentiality and good anti-proliferative effects. Compound enhanced apoptosis and caused cell cycle arrest in the Pre-G1 and S phases. Compound boosted the level of the apoptotic caspase-3 and inhibited the level of TNF-α and IL-6 in tumor cells. Molecular docking and molecular dynamics (MD) simulations indicated the outstanding binding potential of compound against VEGFR-2. Compound is a good candidate for the creation of a novel antiangiogenic lead anticancer medication.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17568919.2024.2421150DOI Listing

Publication Analysis

Top Keywords

vegfr-2 inhibitors
12
vegfr-2
5
compound
5
design synthesis
4
synthesis nicotinamides
4
nicotinamides immunomodulatory
4
immunomodulatory vegfr-2
4
inhibitors apoptosis
4
apoptosis inducers
4
inducers nicotinamide-based
4

Similar Publications

Targeted therapy is preferable over other therapeutics due to its limitation of drawbacks and better pharmaceutical outcomes. VEGF and its receptors have been observed to be hyper-activated in many cancer types and are considered promising targets for assigning anticancer agents. The current study is directed towards synthesis of novel antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with VEGFR-2 properties.

View Article and Find Full Text PDF

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors.

J Xenobiot

December 2024

Cancer Biology and Therapy Laboratory, School of Applied and Health Sciences, London South Bank University, London SE1 0AA, UK.

The vascular endothelial growth factor receptor 2 (VEGFR2) and the hepatocyte growth factor receptor (C-Met) are critical receptors for signaling pathways controlling crucial cellular processes such as cell growth, angiogenesis and tissue regeneration. However, dysregulation of these proteins has been reported in different diseases, particularly cancer, where these proteins promote tumour growth, invasiveness, metastasis and resistance to conventional therapies. The identification of dual inhibitors targeting both VEGFR-2 and c-Met has emerged as a strategic therapeutic approach to overcome the limitations and resistance mechanisms associated with single-target therapies in clinical settings.

View Article and Find Full Text PDF

Decidualization of endometrial stromal cells is a prerequisite for successful embryo implantation and early pregnancy. Decidualization dysregulation results in implantation failure. In our previous study, we reported that PAI-1 is abnormally downregulated in the endometrial tissue samples of patients with recurrent implantation failure.

View Article and Find Full Text PDF

New phthalazine-derived inhibitors for VEGFR-2 were synthesized for anticancer evaluations. Also, docking studies were performed to explore the suggested binding orientations of the novel derivatives inside the binding site of VEGFR-2. The achieved biological data were extremely interrelated to that of docking study.

View Article and Find Full Text PDF

This study aims to investigate the effect and mechanism of the herb pair Agrimoniae Herba-Coptidis Rhizoma in inhibiting angiogenesis in the colorectal cancer inflammatory microenvironment by using the method of network pharmacology and the zebrafish model. The method of network pharmacology was employed to obtain the active components, potential core targets, and signaling pathways regulated by the herb pair in inhibiting angiogenesis in the inflammatory microenvironment of colorectal cancer, on the basis of which the underlying mechanism was predicted. The zebrafish model of colorectal cancer was established, and the inflammatory microenvironment was modeled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!